C-DB8NScripta Therapeutics
transcription factors, AI/ML, patient-derived models
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DB8N
C-DB8NC-DB8Ntranscription factors, AI/ML, patient-derived models
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Oliver's Outdoor Adventures LLC | Feeling grateful to be elevated from Bronze Sponsor to Silver Sponsor and to continue being part of the Ducks Unlimited family
Blog | AM Belgium - Professional Magnetic Heads About us Our products Magnetic heads Audioheads Sensors Manufacturing Services Applications FAQ Blog Contact About us Our products Magnetic heads Audioheads Sensors Manufacturing Services Applications FAQ Blog Contact Our blog Verba volant, scripta manent 2025/04/05 Axpona 2025, booth 9108 Also in 2025, we AM Belgium will be an exhibitor @ AXPONA (Audio Expo North America), America’s largest audio show, now in its 16th year, is set to return to the Schaumburg Convention Center from April 11-13, 2025. The event will showcase the latest in high-end
%PDF-1.6 %���� 978 0 obj > endobj 1056 0 obj >/Filter/FlateDecode/ID[ ]/Index[978 147]/Info 977 0 R/Length 168/Prev 313714/Root 979 0 R/Size 1125/Type/XRef/W[1 3 1]>>stream h�bbd```b``� "׀� l� ��| $S�@�{�$��0ɫV� "�Հ�?�\&Fp�eF�AA�g��� �HS8X endstream endobj startxref 0 %%EOF 1124 0 obj >stream h�b```b``�������� ĀB@1�), �Uu i ��iK�1���```�d���P�1Q٭W�$��"���� �������������ZTR^\YUQZV]���WPX���Q�Y���������6�w��}�L��-��]�@��� �0.cXBd]�����Ӧ�%����G�{��F �j0 � h@�1� �0L(�EA"8cd�2����- c`�`�`�`(d� �CB���,��@�?���ьI�q>K1�fo�3LL�L��V … 43a1b-76a2-4021-9690-37a0a256128a uuid:1fbc6c79-c897-4c31-b1f6-7ab0e3cd5d7a 114 application/pdf Theriault, Christl Adobe PDF Library 15.0 State of Maine 1.1 1 endstream endobj 113 0 obj >stream h47Q0P�47U01Rf �F� 66����y% ���ޙ)�� y� � � RY�� ���ZlgWm UlaVl&M��9D��; �(��lwv�� �B,6�SF��� �l#3���H:[ endstream endobj 114 0 obj >stream h�d�� �@��W�;*gD�BQZ%�G�C�۸�� �t�?� ��b�#� ��Z&��rd�S��x�y�[�, P+3����+����H��e,#y؊�����\�L���T�ZݑA�0ÍXaM������4Lz��9
Melbourne Rare Book Fair Menu The 2026 Fair Rare Book Week Exhibitors Find an Exhibitor Exhibitor Directory Highlights News Log-In Home Littera Scripta Littera Scripta Member of ANZAAB - Australia Antique Prints Art Early Printed Leaves Ephemera Manuscripts Medieval Illuminated Manuscript Leaves Australia's specialist dealer in medieval and renaissance documents. Original illuminated manuscript leaves, 11th to 16th centuries. Original printed leaves, 15th to 17th centuries. Books of Hours, Bibles, music, liturgy, secular and sacred commentary. Occasional newsletters of new items and specials. … vacy practices. Close The Fair About ANZAAB The Convenor Latest News Exhibitors Apply to Exhibit Exhibitor Login Find an Exhibitor All exhibitors are affiliated with ILAB and observe ILAB’s strict Code of Usages and Customs requiring books and related material to be accurately and professionally described and guaranteeing the authenticity and genuineness of all material for sale. ANZAAB respectfully acknowledges the Wurundjeri People of the Kulin Nation, who are the Tradition
Virtual Press Office: Trade show news, exhibitor news, online press kits --> Send a News Release --> Blog For Journalists News Solutions Resources --> --> Overview Marketing Public Relations IR & Compliance Agency All Products Contact Us Journalists Blog Become a Member Send a Release --> Order a Press Kit News Solutions Resources --> Search Contact Us +1 973-783-7787 option 0 Home Products Event Organizer Services News Releases Events Press Services Overview Marketing Public Relations IR & Compliance Agency All Products --> News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29
Anne Marije van Harten - Apollo Health Ventures | LSX USA Congress Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Executive Partnering Congress Sept 23-24, Forums Sept 22, 2026 BCEC, Boston, USA Home home Agenda expand_more Day 0 Day 1 D … SA Home home Agenda expand_more Day 0 Day 1 Day 2 Speakers Showcase expand_more Apply Showcase Agenda Investor Feedback Panel Investors expand_more Investor Criteria Syndication Drinks 2025 Investor Attendees Partnering expand_more PartneringONE Partnering Upgrades Networking expand_more Speed Networking Investor Syndication Drinks Sponsor & Partner expand_more Partner With Us Sponsors Partners Sponsorship Brochure More expand_more Plan Your Visit Floorplan Biotech Week B
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.6 %���� 2 0 obj >/Border[0 0 0]/P 3 0 R>> endobj 4 0 obj >/Border[0 0 0]/P 3 0 R>> endobj 5 0 obj >/Border[0 0 0]/P 3 0 R>> endobj 6 0 obj >/Border[0 0 0]/P 3 0 R>> endobj 1 0 obj >/XObject >>>/Type/XObject/Subtype/Form/BBox[0 0 595 842]/Matrix[1 0 0 1 0 0]/FormType 1>>stream x��UKO�Fn��OYe��.If�u��s ������p��`B���ʜSm{fl3 ,�]U]_�WU��~�x�@� Lb��o-s���Ļ�__Q��z����K���y�R 6�c��ug�yg}���=q!� ��Z ���� �\y�㛧*�Fp6-ӻy�q�� �ih���%A��cE��i�i~�a���b�V��*���l���,��/�Z`A��o���`ҧ^�( �5L�~N4TRTut|�ת� c�'Ä�J���M�|"�X�� ������O��mV7K�X�РF�S�E��CrA�quA���7\�s� �l������gc����
Scripta Therapeutics Advances Disease-Modifying Therapies | Bioscience Today posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … efficacy evidence, introducing significant uncertainty to the Biologics License Application (BLA) timeline. 2. This shift contradicted previous FDA alignment, derailing uniQure's anticipated early 2026 BLA filing and catching many investors off guard. 3. Multiple class action lawsuits have since been filed, alleging uniQure misled investors regarding FDA alignment and the likelihood of accelerated approval. Understanding these regulatory shifts is crucial for investors naviga … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catal
Medieval Studies CALLS FOR PAPERS | I am thrilled to share the Call for Papers for our upcoming international conference exploring the heavens in the Middle Ages:
%PDF-1.4 %�쏢 %%Invocation: path/gs -P- -dSAFER -dCompatibilityLevel=1.4 -q -P- -dNOPAUSE -dBATCH -sDEVICE=pdfwrite -sstdout=? -sOutputFile=? -P- -dSAFER -dCompatibilityLevel=1.4 -dAutoRotatePages=/None -dPDFSETTINGS=/default -dDetectDuplicateImages=true %%+ -dEmbedAllFonts=true -dSubsetFonts=true -dCompressFonts=true -dNOPAUSE -dQUIET -dBATCH -f ? 6 0 obj > stream x��TM�I ���� U Rk�>}d�h�2�F F FCfv�I�@���UW+�F9��b�=ۯ�!�B�~{�0l5�����W�*�'Q �c��>�j����n#L/��E;I�a�#gMȚ2�X�A�s�/C�� I-�k��A}ɰZ|�@n[Jm)7Op�Imp��e.��gD �x F�� :�s��QXASk��� ��wC,�� > stream x��U�nG��+�8sH�k����,E@;�CA … �������Y��r�C� �%S�4�����jz>�Wk8��j�3������-��}��S�����5K)�䧺����YT�g0�����rFPŒ��E���l�Q!)I� P,$}"/�7Uvf��"K������M�i%�K3�b\�� %��)����O�A���F�LFN9�� �:�ga�ò���9��[�8�n?J)�2��#U���C���?��nO��4G��S�̞��tU�ϳ�4I�}�7Z�8�+A�"bD� ����v�p��3��H�C�ӦZʕ�Y��*?����SRix�pINI����ó�>�|[�2 g�P)��%_�:�0�x�P�ry�0|D��3�K���S�v������ �N�S�� ��r� )K��=��!�X��6�x�}q Թkx���3/&�|E�LĔ��%����aa��rg��*�}�����u�qĸ���@e+��:� �H�(���5J�Ԛ�u�j y�7$n�AX� �s �4�̤ … ��!_��Pe�H'�y.@�u�����1F \�g �S�h�s��^�r�p�UGF�8�),n/��m��4�G.==Rhf]rFp��rĞ���3t�L�7�ׯ�+��&T%�S�إqba����L�� NC �9I&�` @(uē ���4� 4��[�v��S�C��f����@���(�� �#b�H����� Bҵ�6bR�?�� I�eq&=0KG��6X �k;���ٶ��6��)s �4���%#Bۑ�ݢM��tJ�1j=��Q4��@ ǧ8��-%��g��\�L��r�����?�T� �S��`LB� ��H86mjV�$�Ft��5����隆���I!�_�OC�|� -H�&]�� ���kzx ���w� ĄJ=���s�%���e{P��UK)&-Jyr���"��~�/ U�$p� �"�f"��FB��mJ����Ȑ�������)��,>�S�h�?��PT��M�����f + [�7�]L�RԪ�Re� … �����XPQ���ߣ��w����JE* "�N��О&�m�G�|"N`�DK�����-lO��Q*MT *;}�f%�i��8mB�RFp;��}GHoӉ/%�'��ŠJ�] �u��/�m Z�RȚ����I ��� �=a+ ��2p������ �A����.p�'iBO �ա+]*e������[ ~�Y|�>��8O�B�.�_dC�|-p���R�l�+���ˤ�JH� ~�?�C����i�J�� �/ԢTp�QcL��� �?��y�����b&@��$8ۜ%�J�J�Z D0��Ò�_����>�^J� �� �@R��4�p|mg$I��0i5J�"���H)!}�*m�6�˔Q��K�P� N���� ��)(�[�x�˒��#N#�xơT� �3 j�HV�,|�q� ���fL�E'�Q&z���q��97-b��*^ &쑸wآ�r�t� )R�(f��3�:���-�[��� )����-&R���s:F`
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Quantum Health Showcases Continued Innovation that Lowers the Total Cost of Care | Quantum Health Skip to main content What we do Who we serve Resources Company Talk to sales What we do Who we serve Resources Company Login Download our mobile app Login Talk to sales Newsroom • May 7, 2026 • 5 min read Quantum Health Showcases Continued Innovation that Lowers the Total Cost of Care On this page On This Page Announced from their annual Connect conference, the company highlighted new approaches to pharmacy cost reduction, virtual primary care, built-in Centers of Excellence and more. New pharmacy
INSPIRE You need to enable JavaScript to run this app. tag. To begin the development, run `npm start` or `yarn start`. To create a production bundle, use `npm run build` or `yarn build`. -->
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Data for Drug Savings | Leader's Edge Magazine Subscribe Leader’s Edge Magazine Newsletter Updates The Leader’s Edge Podcast Subscribe Leader’s Edge Magazine Newsletter Updates The Leader’s Edge Podcast P&C Health+Benefits Industry Brokerage Ops Lifestyle Magazine Podcast Subscribe Leader’s Edge Magazine Newsletter Updates The Leader’s Edge Podcast Health+Benefits Vital Signs the June 2026 issue Data for Drug Savings Q&A with Eric Levin, Co-Founder and CEO, Scripta Insights, and Miriam Paramore, Founder and CEO, RxUtility By Tammy Worth Posted on May 26, 2026 Scripta is a technology c … ve to pay full price until they hit their deductible. If you carve out and help fund a cash-pay program, you can get [Zepbound] for $299 on [Eli] Lilly. Then you can set up an arrangement with the save card where you can split it 50/50 or you pay $200 and the member pays $100. Things are always changing, so two months from now, there may be a better program. I also think PBMs are going to come up with some alternatives. When there’s so much pressure on an issue at some point
ESFRI Scripta Series | www.esfri.eu www.esfri.eu Search Login ESFRI MOS Contact About The Forum Objectives & Vision Background Structure How ESFRI works Media Kit The Working Groups Past Working Groups Long-term Sustainability Group Strategy Working Group & Task Forces Environment Strategy Working Group & Task Forces Data, Computing and Digital Research Infrastructures Implementation Group Implementation Strategy Working Group & Task Forces Health and Food Strategy Working Group & Task Forces Monitoring Committee Strategy Working Group & Task Forces ESFRI-EOSC Coordination … ion of Europe and to strengthen its international outreach. more Find RI events Submit RI events Embedded video for ESFRI Roadmap 2021 Teaser Contact Us [email protected] ESFRI Secretariat ESFRI Newsletter Register to ESFRI newsletter to receive the latest news on the field of research infrastructures E-mail * Leave this field blank This website has been developed and is being maintained on behalf of ESFRI by the StR-ESFRI3 project which has received funding from the European … rom the European Union’s Horizon Europe Research and Innovation Programme under Grant Agreement n° 101058092 Curated and powered by Athena RC Home Sitemap Privacy Policy Contact Developed by CITE
The Conference Board Employee Health Care Conference New York is SOLD OUT. We're all charged up and ready to save you, and your members, on Rx! Proud to be the official conference sponsor keeping… | Scripta Insights LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Scripta Therapeutics News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu Biology decoded, disease undone Modulating transcription factor activity to restore health Drug discovery is coming from the wrong direction: targeting the downstream consequences of disease rather than the underlying biological causes. It’s time to flip the script. By focusing on unde rstanding and manipulating the master controllers of biology, we’re searching for drugs with the pote
SeedtoB Capital SeedtoB SeedtoB About Team Portfolio Blog News Contact Portfolio News and Events The latest news and updates from our portfolio companies. Moonlight Therapeutics Begins First Human Trial of Microneedle Peanut Allergy Treatment June 2026 Learn More Scripta Insights partners with Quantum Health May 2026 Learn More Biotia Announces Major Clinical Milestone for NGS-Based UTI Diagnostic April 2026 Learn More TERN Group wins top honors at Economic Times Entrepreneur Awards 2026 April 2026 Learn More AngelEye Health Acquires SupportSpot March 2026 Learn More Marvix AI joins AAN’s Prac … / Co-founder Anju Mathew named finalist of "2023 Women In Technology (WIT) Award" October 2023 Watch on youtube SeedtoB Capital leads $1.5 million in Pediatric Vaccine management platform Canid Septermber 2023 Read more at MarketWatch Mark Cuban Cost Plus Drug Company and Scripta Insights Team Up to Give Patients Transparent Drug Pricing and Medication Options August 2023 Read the full press release OncoLens named to Inc.5000 list of fastest growing private companie … ess release Moonlight Therapeutics Receives Multi Million Dollar Clinical Trial Grant to Evaluate MOON101 for Peanut Allergy July 2023 Read the full press release Scripta Insights Expands Leadership Team with Executive Hires, Adds Deep Industry Expertise to Power Next-Level Growth June 2023 Read the full press release OncoLens and SARC Strategic Partnership Drives Nationwide Initiative for Enhanced Sarcoma Patient Care June 2023 Read the full press release Feel therapeutics h … to tell us about what you're building and how we can help. Full Name Email Submit SeedtoB Portfolio About Contact Team Blog News visit Seedtob's Twitter page visit Seedtob's LinkedIn page © 2026 SeedtoB Capital. All rights reserved.
Scripta Insights Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech sta
Scripta Therapeutics Secures $12M in Seed Funding | This Week in Digital Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
--> Sponsorship Opportunities | Bowie State Skip to the content Toggle Search Close Search Search Bowie State University website Submit Search Toggle Menu Visit Apply Request Info About Toggle Sub Menu At a Glance History News Events Calendar Strategic Plan Administration & Governance Offices & Services Equity Compliance - Title IX Bulldog Pride Accreditation Sustainability BSU Foundation Admissions & Aid Toggle Sub Menu Apply Online Undergraduate Admissions Graduate Admissions International Admissions Military Services Visit Us Tuition & Fees Financial Aid Academics Toggle Sub
About the Journal | Scripta Manent Skip to main content Skip to main navigation menu Skip to site footer Open Menu About About the Journal Submissions Editorial Team Publication Ethics and Publication Malpractice Statement Research data management (notes for authors) Use of Generative AI in Preparing Articles Privacy Statement Contact Current Archives Archives 2005–2022 Announcements Other UL Press Journals Search Register Login Home / About the Journal About the Journal Focus and Scope Scripta Manent , Journal of the Slovene Association of LSP Teachers, is a peer-reviewed open access journal … e theory and practice in the LSP teaching profession. Authors are encouraged to submit manuscripts on applied and theoretical research in LSP, including: - genre-based research, - multimodal texts, - lexicology and lexicography, - translation studies, - intercultural studies, - language policy, - teaching/learning, - curriculum and syllabus design, - teaching and learning materials design, - language teaching methodology, - assessment and evaluation, - teacher roles and educa
About the Journal | Scripta Mechanica Skip to main content Skip to main navigation menu Skip to site footer Open Menu Submit a paper Current Issue Online First For Authors Author guidelines Paper Word Template Publication Ethics Statement Manuscript preparation About About the Journal Editorial Team Journal Metrics and Performance Indexing and Recognition Privacy Statement Archives Contact Search Register Login Home / About the Journal About the Journal About Scripta Mechanica Scripta Mechanica (SCRMEC) is an international, peer-reviewed, open-access journal that advances knowledge in the fiel … e Authors retain copyright of their articles published in Scripta Mechanica and grant the journal the right of first publication under the Creative Commons Attribution License (CC BY 4.0). This allows others to share and adapt the work with proper attribution to the authors and original source. Publisher and Sponsorship Scripta Mechanica is published by the Italian Scientific Society of Mechanical and Machine Design (AIAS-ETS) and hosted on the Open Journal Systems (OJS) plat
Astrobiology English About Goals History Motu Proprio Statutes Governance Pius XI Medal Casina Pio IV Contacts and Maps Editorial Guidelines Magisterium Leo XIV Francis Benedict XVI Saint John Paul II Saint Paul VI Saint John XXIII Servant of God Pius XII Pius XI Benedict XV Academicians Scientific Disciplines Ordinary Academicians Honorary Academicians Academicians Perdurante Munere Nobel Laureates Deceased Academicians Former Academicians Events Workshops Plenary Sessions Statements Publications Acta Scripta Varia Extra Series News Homepage Publications Scripta Varia Astrobiology Proceedings
Einstein Helps Sponsor Scripta Mathematica - Einstein and Yeshiva University - University Libraries at Yeshiva University chat loading... Skip to Main Content YU Libraries on the Wilf and Beren Campuses are open to current YU students, faculty, staff members, and alumni/ae. Alumni/ae must first register with and present proof that they are fully vaccinated to the Office of Alumni Affairs . Read more ... --> Yeshiva Home Ask Us! - Live Chat --> Ask Us! Email us anytime Chat with us Schedule a Research Consultation Feedback & Suggestions Toggle navigation Yeshiva University Lib … a full-fledged liberal arts college with one foot in the world of contemporary scholarship. “The only mathematical journal published under Jewish auspices," Scripta helped prove to him that Yeshiva College was not only a recipient and transmitter of traditional Jewish learning but a contributor to modern secular learning as well. Founded under the editorship of Dr. Jekuthiel Ginsburg, the journal produced its first issue in September 1932. By December 1933, when R
--> PRESS RELEASE ARCHIVE | Scripta Insights top of page Member Support: (866) 572-7478 CONSULTANTS & PLAN SPONSORS We're the Rx Navigation™ Company Get your members The Right Meds at The Best Price ™, while reducing your pharmacy benefit spend–without changing PBMs. SOLUTIONS Rx Navigator | Fiduciary Protection Program GLP-1 Navigation | Member Incentive Rewards Provider Navigator | Cash Pay Integrations TECHNOLOGY Scripta’s Med Mapper™ AI Software ABOUT Team | Board | P&T Committee CASE STUDIES Realized Savings | Testimonials INSIGHTS Blog | Ar … ; APRIL 02, 2020 Scripta Insights Wins a Validation Institute Health Value Award Scripta Ties for Silver Award in the Spotlight Category Among Innovative Companies in the Healthcare Industry Read More > MARCH 23, 2020 Scripta Insights Offers Expert Doctor Tips on How to Get Your Prescriptions Safely During the COVID-19 Outbreak Fill Prescriptions Online, Request an Early Refill and Consider Telehealth to Get Medication, Stay Safe and Healthy Read More > JANUARY&n
Scripta Insights and Quantum Health Announce Strategic Partnership for Pharmacy Cost Reduction Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Phot … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Flipping the script: Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Flipping the script: Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity November 13, 2025 | 3 min read Twitter LinkedIn Facebook Email Print $12 million seed funding round led by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Scripta Insights Planning for Massive Growth in 2023, Building on its Proven Ability to Empower Smarter Prescription Buying Decisions, Lower Rx Benefit Costs for Clients, and Drive Better Health Outcomes Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All Ne … he full burden of Rx. Personalized Medications Based on DNA In 2023, Scripta is rolling out a personalized medicine program for select clients. Scripta has partnered with RxMapper, a personalized medication platform and telehealth consult practice developed in collaboration with Mayo Clinic. RxMapper sequences and analyzes a patient's DNA and utilizes those results to identify which drugs the patient should and should not take based on their DNA, resulting in lower costs and … tected] | 646-824-5186 [1] Spear, B.B., M. Heath-Chiozzi, and J. Huff, Clinical application of pharmacogenetics. Trends Mol Med, 2001. 7(5): p. 201-4. [2] Watanabe, J.H., T. McInnis, and J.D. Hirsch, Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother, 2018. 52(9): p. 829-837. SOURCE Scripta Insights 21 % more press release views with Request a Demo × Modal title Also from this source Scripta Insights and Quantum Health Announce Strategic Pa … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Scripta Insights Secures Series B Funding, Raises $42M Total, Revolutionizing the Way Americans Shop for Prescription Drugs | Eastside Partners About Team Entrepreneurs Portfolio News Contact LP Login Search Search for: News by Month News by Month Select Month February 2026 January 2026 December 2025 October 2025 August 2025 December 2024 June 2024 April 2023 February 2023 December 2022 October 2022 September 2022 August 2022 June 2022 April 2022 February 2022 January 2022 December 2021 August 2021 April 2021 August 2020 July 2020 June 2020 April 2020 January 2020 December 2019 November 2019 A … llCloud Atlanta Awarix Birmingham BrightWhistle Denver Exits Financial Services Fund News HCIT Healthcare Hirtle Huntsville Hygia inMotionNow IT Jvion Medseek Mobile NBoC nLogic NucSafe Optimal PeopleTec ProctorU Rachio Raleigh Scripta SMR Torch 18 December 2024 Scripta Insights Secures Series B Funding, Raises $42M Total, Revolutionizing the Way Americans Shop for Prescription Drugs Boston, MA – “Consumerism in healthcare” is a popular catch phrase, but whe
Scripta Insights Partners with Quantum Health | Max Hooker posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
--> BOARD | Scripta Insights top of page Member Support: (866) 572-7478 CONSULTANTS & PLAN SPONSORS We're the Rx Navigation™ Company Get your members The Right Meds at The Best Price ™, while reducing your pharmacy benefit spend–without changing PBMs. SOLUTIONS Rx Navigator | Fiduciary Protection Program GLP-1 Navigation | Member Incentive Rewards Provider Navigator | Cash Pay Integrations TECHNOLOGY Scripta’s Med Mapper™ AI Software ABOUT Team | Board | P&T Committee CASE STUDIES Realized Savings | Testimonials INSIGHTS Blog | Articles | Researc … tour invests in early stage companies focused on information technology and the application of technology into the financial services, enterprise SaaS and digital media sectors. Bob’s investments include BounceX, Covr, Dstillery, Fevo, Pathgather, Punchbowl, Radius Networks, Scripta, Simpli.fi, Slice, Source3, SwapDrive, Syndio, Trialjectory and Voxy. Prior to launching Contour in 2006, Bob was one of the three managing partners of Flatiron Partners in New York C … Avery leads the healthcare & benefits strategy for the firm’s venture fund. He currently holds board roles with Ideon, Valera Health and LegalMation and is active in supporting 20+ current investments across Aquiline’s portfolio. Prior to joining Aquiline, Avery worked as an investment banker at Cain Brothers, a division of KeyBanc Capital Markets, where he focused on advising growth-stage companies in the healthcare technology, healthcare services and … rtner at Eastside Partners where he has been a limited partner in each Eastside fund and its predecessor funds (SETFUND) since 1998. He co-invests in portfolio companies, provides board member services and strategic guidance, and conducts day-to-day management as needed. Sandy has served as President at ProctorU, an online proctoring service for academic exams and professional certifications; President at HYGIA Health Services, a re-processor of certain single-use, non-invasi
--> SCRIPTA NEWS | Scripta Insights top of page Member Support: (866) 572-7478 CONSULTANTS & PLAN SPONSORS We're the Rx Navigation™ Company Get your members The Right Meds at The Best Price ™, while reducing your pharmacy benefit spend–without changing PBMs. SOLUTIONS Rx Navigator | Fiduciary Protection Program GLP-1 Navigation | Member Incentive Rewards Provider Navigator | Cash Pay Integrations TECHNOLOGY Scripta’s Med Mapper™ AI Software ABOUT Team | Board | P&T Committee CASE STUDIES Realized Savings | Testimonials INSIGHTS Blog | Articles |
Pillar VC Portfolio Companies | Science and Tech Founders Skip to content Our Approach Our Focus Our Belief Founder Resources Common Stock Companies Team Founder Resources Founder Playlist Founder Resources Encode Pillar Events Our Approach Our Focus Our Belief Founder Resources Common Stock Companies Team Founder Resources Founder Playlist Founder Resources Encode Pillar Events X (Twitter) Linkedin Scripta helps employers analyze pharmacy transactions and compare them to PBM contracts, generating immediate savings. scriptainsights.com Eric Levin CEO, Scripta Categories FinTech , Healthcare Co … , 9th Floor, Boston, MA 02116 X (Twitter) Linkedin Announcing Pillar VC's $175M Fund IV
Scripta Therapeutics | Insights from Scripta News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu News Ready to dive deep into the groundbreaking world of transcription modulation? Join us on the latest discoveries with expert insights, and all our latest news. All Insights Corporate Team news All Insights Corporate Team news All Insights Corporate Team news Insights Multi-factorial diseases require a multi-target lever Transcription factors present an opportunity
Scripta Therapeutics — Health funding & jobs | MapCo S Scripta Therapeutics UK · Health · Latest deal Nov 13 Get Free Analysis on 30+ AI Deals Daily Subscribe Free Read by strategy teams, founders, investors Search jobs board --> Deals ❤️ Jobs Find 30,000+ jobs at newly funded AI companies for your next opportunity. Browse jobs ↗ scripta-therapeutics.com More Health Selected Investors: Oxford Science Enterprises , Apollo Health Ventures Latest Scripta Therapeutics Signals Synthesising company profile Reading press coverage to extract founders, customers, traction signals and competitive po
Scripta Therapeutics Ltd – StudySmarter – Talents Explore Careers StudySmarter Job Board Find your dream job on the largest job board for Gen-Z worldwide. Find a job Featured Companies Featured Universities For Companies In the spotlight All Jobs Over 2 million jobs are waiting for you. Featured Companies Top companies we pre-selected for you. StudySmarter App Discover our mobile app to take your studies anywhere. StudySmarter Blog Trusted advice for anyone who wants to ace their studies & career. Start Hiring Start Applying Start Applying StudySmarter Job Board Find a job Feat
Member profile: Scripta Therapeutics | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search secto … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association Member profile: Scripta Therapeutics Scripta Therapeutics Industrial Biotech Funding stage: Seed Technology type: Tech
Scripta: Reprogramming Alzheimer’s through transcription factors | Claire Brown LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A
Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity - TOSP This site uses cookies to bring you the best experience. Find out more Skip to main content Contact Us Occupiers Login Discover the Park About Us Our Team News Map Find Us Space at the Park Available Space Developments Meeting Rooms Enquiries Our Community Who's Here Our Ecosystem Our Amenities What's On Careers Contact Us Occupiers Login ↑ News Home News Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity Scripta Th
All Dr Peter Hamley (CEO of Scripta Therapeutics) articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business W
Peter Hamley, Scripta Therapeutics | Careers in Discovery Cancel Home Subscribe Profile Careers in Discovery https://feed.podbean.com/careers-in-discovery/feed.xml 15.8K Downloads 211 Episodes Share RSS Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influential figures, the work they are doing, how they got to where they are and what advice they’d give their younger selves. Brought to you by Singular: Building Brilliant Biotechs. Connect with us at: LinkedIn:
Scripta Therapeutics: $12 Million Closed To Advance Biology-First Drug Discovery Targeting Transcription Factor Activity VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Scripta Therapeutics: $12 Million Closed To Advance Biology-First Drug Discovery Targeting Transcription Factor Activity By Amit Chowdhry • Nov 14, 2025 Scripta Therapeutics: $12 Million Closed To Advance Biology-First Drug Discovery Targeting Transcription Factor Activity Scripta Therapeutics, an Oxford-based techbio startup developing disease-modifying drugs that alter transcription factor
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Scripta Therapeutics: Funding, Team & Investors | Startup Intros Home / Organizations / Scri
#drugdiscovery #biotech #techbio #aidrugdiscovery #scripta #venturecapital #startup | Scripta Therapeutics | 26 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … kthrough, a team of researchers from the University of Washington, led by Nobel Prize-winning scientist David Baker, used 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 to create functional antibodies, potentially transforming how we develop 𝗹𝗶𝗳𝗲-𝘀𝗮𝘃𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀. This matters because antibodies are 𝘁𝗵𝗲 𝗯𝗮𝗰𝗸𝗯𝗼𝗻𝗲 𝗼𝗳 𝗺𝗼𝗱𝗲𝗿𝗻 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. They’re used to 𝗰𝗿𝗲𝗮𝘁𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 for cancer, autoimmune diseases, and countless other conditions.
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Peter Hamley, Scripta Therapeu…–Careers in Discovery – Apple Podcasts Search Home New Top Charts Search 17 December 2025 42 min Peter Hamley, Scripta Therapeutics Careers in Discovery Play This week on Careers in Discovery , we’re joined by Peter Hamley, Founder and CEO of Scripta Therapeutics. Peter didn’t follow the typical founder path. After a long and successful career in big pharma R&D and business development, he made the leap into Biotech with a mission: to unlock the potential of transcription factors in treating neurodegenerative diseases. What followed was
Peter Hamley, Scripta Therapeu... - Careers in Discovery - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ١٧ ديسمبر ٢٠٢٥ ٤٢ د Peter Hamley, Scripta Therapeutics Careers in Discovery تشغيل This week on Careers in Discovery , we’re joined by Peter Hamley, Founder and CEO of Scripta Therapeutics. Peter didn’t follow the typical founder path. After a long and successful career in big pharma R&D and business development, he made the leap into Biotech with a mission: to unlock the potential of transcription factors in treating neurodegenerative diseases. What followed wa
Scripta featured in Drug Target Review News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu 19 Jan 2026 Insights Scripta featured in Drug Target Review At Scripta, we're moving beyond a target-centric mindset to an appreciation that disease mechanisms are complex and often underpinned by transcriptional dysregulation. Dive into how we’re rethinking drug discovery through the lens of transcription factor biology in a new article featured on the front page of Drug T
Peter Hamley, Scripta Therapeu… - Careers in Discovery - Apple Podcasts Search Home New Top Charts Search December 17, 2025 42 min Peter Hamley, Scripta Therapeutics Careers in Discovery Play This week on Careers in Discovery , we’re joined by Peter Hamley, Founder and CEO of Scripta Therapeutics. Peter didn’t follow the typical founder path. After a long and successful career in big pharma R&D and business development, he made the leap into Biotech with a mission: to unlock the potential of transcription factors in treating neurodegenerative diseases. What followed w
SBH BioVenture seeks early-stage biotech founders for collaboration | Lisa Portney posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Scripta Therapeutics raises $12M to map diseases with AI and imaging | StepUp.One Fundraising posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … kthrough, a team of researchers from the University of Washington, led by Nobel Prize-winning scientist David Baker, used 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 to create functional antibodies, potentially transforming how we develop 𝗹𝗶𝗳𝗲-𝘀𝗮𝘃𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀. This matters because antibodies are 𝘁𝗵𝗲 𝗯𝗮𝗰𝗸𝗯𝗼𝗻𝗲 𝗼𝗳 𝗺𝗼𝗱𝗲𝗿𝗻 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. They’re used to 𝗰𝗿𝗲𝗮𝘁𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 for cancer, autoimmune diseases, and countless other conditions. … Primaa’s journey as new investors in partnership with MH Innov’, the corporate fund of Malakoff Humanis , alongside SWEN Capital Partners and other backers. Primaa develops cutting-edge AI solutions for digital pathology, including Cleo Breast and Cleo Skin, already deployed in leading hospitals such as Institut Curie and Greater Paris University Hospitals - AP-HP . These tools help pathologists detect and analyse cancer faster and more reliably, enhancing both accuracy and
Flipping the script: Scripta Therapeutics raises $12 million to find disease-modifying drugs that alter transcription factor activity | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Dev … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Flipping the script: Scripta Therapeutics raises $12 million to find disease-modifying drug
Scripta Therapeutics Raises $12M to Revolutionize Drug Discovery | Bioscience Today posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … sciences vehicle, Arkin Bio Ventures III, with $100 million in commitments. The fund will target early-stage biotechs in oncology, immunology, inflammation, and rare diseases, planning to invest in 10-12 companies globally. We caught up with Dr. Pini Orbach , the fund's Managing Partner, who outlined a distinctly pragmatic philosophy. He emphasized that while technological platforms like AI are valuable, the fund's primary focus is on strong underlying biology and clear paths … erlying biology and clear paths to clinical proof-of-concept. "We are a 'no-BS' fund," Dr. Orbach stated. "We are very straightforward, science-driven, pragmatic, and practical. If you have something that is genuinely best-in-class, backed by compelling high-quality data, you should approach us." The fund positions itself as an active, hands-on partner, aiming to help portfolio companies bridge the gap from promising science to clinical validation. This strategy builds on Ark … #HealthcareInnovation #Pharma #Investment Arkin Bio Ventures III: $100 million fund for transformative therapies https://druganddeviceworld.com 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Vatche Bartekian 5mo Report this post 💡 Capital is only the starting point. Execution determines the outcome. This news is a strong signal of continued investor confidence in innovative biotech platforms. But as every sponsor quickly learns, funding alon … sciences vehicle, Arkin Bio Ventures III, with $100 million in commitments. The fund will target early-stage biotechs in oncology, immunology, inflammation, and rare diseases, planning to invest in 10-12 companies globally. We caught up with Dr. Pini Orbach , the fund's Managing Partner, who outlined a distinctly pragmatic philosophy. He emphasiz
Finding a co-founder for a hardware medtech is its own kind of work. After 8 months of meeting people who almost-believed in VAir, I had stopped expecting the conversations to lead anywhere. Then one… | Ekaterina Kukhtenko LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your cho … round, joined by JME Ventures , Big Sur Ventures , Masia , and a new UK stealth fund. 🫶 Welcome to the Norrsken Evolve portfolio, Alex Ward , Caelan Anderson , and the rest of the Tolemy Bio team! 147 4 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Aashrita Narayan 1mo Report this post Tolemy Bio is building a control center for cell biology; with currently cell bio data being scattered across notebooks, spreadsheets, lab machines, an … , and joined by JME Ventures , Big Sur Ventures , Masia , and a new UK stealth fund. Alex Ward , Caelan Anderson , and team Tolemy Bio , congrats on this round and keep the good news coming! AND - they’re right now hiring in Barcelona! Check opportunities via link in comments. 46 3 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Alexander Leutner 1mo Report this post 𝐏𝐞𝐨𝐩𝐥𝐞 𝐭𝐡𝐢𝐧𝐤 𝐭𝐡𝐞 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐢𝐧 𝐨𝐮𝐫 𝐬 … discover and develop new therapeutics — from platform innovation to real-world application. This panel looks at what that means in practice. Delighted to welcome Beverley Carr ( CHARM Therapeutics ), Peter Hamley ( Scripta Therapeutics ) and Liam Atkinson ( Ellison Institute of Technology Oxford ) for this discussion. This panel will be moderated by Ramy Alesi Slama , MD of Consulting at Oxford University Biotech Society . Looking forward to what promises to be a highly insi
Portfolio | Eastside Partners About Team Entrepreneurs Portfolio News Contact LP Login Current Portfolio Previous Investments Portfolio TextUs Denver, CO – TextUs is a leading mobile communications software platform for businesses that want to increase read and response rates while engaging in real-time text message conversations with customers, leads, employees and candidates. Scripta Insights Boston, MA – Scripta provides software-enabled pharmacy cost containment solutions to self-insured employers and health plans. The company offers to its clients both an enterprise B2B offering as … Microsoft® Gold Certified Partner and National Systems Integrator that provides application development, enterprise integration and business intelligence services for companies across the Southeast. (Acquired by NWN Corporation) Emageon Birmingham, AL – Emageon introduced its market leading PACS solution, which allowed physicians and healthcare professionals to manage, access and view multi-specialty medical images across any PC in the hospital. (Exited via IPO: Nasdaq … red by Relatient) SPI Dynamics Atlanta, GA – SPI Dynamics’ Web application security products and services help organizations build and maintain secure Web applications, preventing attacks that would go undetected by traditional Internet security measures. (Acquired by Hewlett Packard – NYSE: HP) Torch Technologies Huntsville, AL – Torch Technologies provides systems engineering, modeling and simulation, and information systems services to governme
Peter Hamley on AI in Drug Discovery with Scripta | Scripta Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag … , on the latest episode of Careers in Discovery. Peter talks about how focussed application of AI can meaningfully improve drug discovery, Scripta's unique take on “lab-in-the-loop”, and how we’re using omics to zero in on the drivers of disease—starting with neurodegeneration. You’ll also hear Peter’s personal journey: from an unexpected start, through big pharma and business development, to building a company to “flip the script” on how we find disease-modifying medicines.
--> Meet Jacqueline Barnett, Scripta’s Vice President of Account Management top of page Member Support: (866) 572-7478 CONSULTANTS & PLAN SPONSORS We're the Rx Navigation™ Company Get your members The Right Meds at The Best Price ™, while reducing your pharmacy benefit spend–without changing PBMs. SOLUTIONS Rx Navigator | Fiduciary Protection Program GLP-1 Navigation | Member Incentive Rewards Provider Navigator | Cash Pay Integrations TECHNOLOGY Scripta’s Med Mapper™ AI Software ABOUT Team | Board | P&T Committee CASE STUDIES Realized Savings |
Litera Scripta | Bounds Law Library Apply Give myBama 3:00pm 06/27/2026 Expand title bar menu Close title bar menu Search the Law Library's Catalog Submit Information Expand Information menu Close Information menu Hours Location Reference Services Circulation Services Directory Book Study Room Book Equipment Research Expand Research menu Close Research menu Databases Guides Legal Links New Books Special Collections Expand Special Collections menu Close Special Collections menu Manuscript Collections Hugo Black Collection Exhibits Occasional Publications Policies Sample Exams Catalog Litera Scr … hool of Law is co-sponsor, with the American Bar Association, of the Harper Lee Prize for Legal Fiction. The winner for 2015 is Deborah Johnson’s powerful and evocative novel The Secret of Magic, set in post-World War II Mississippi. The following is an appreciation of The Secret of Magic, contributed by… Justice Hugo Black Study Reopens August 11, 2015 Litera Scripta is pleased to announce that following significant renovations this summer, the Hugo Black Study at the
Peter's Biotech Investment Insights from Sanofi to Scripta Therapeutics | Tyler Olding posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … rm 2,300 followers 5mo Report this post Servier Unveils €200M Strategic Venture Fund to Back Next-Gen Biotech and Therapeutics https://lnkd.in/ghhFxD4R #ServierVentures , #CorporateVC , #BiotechInvestment , #VentureCapital , #OncologyInnovation , #NeurologyR &D, #LifeSciences , #StartupFunding , #HealthcareInnovation , #EuropeanStartups , #TherapeuticsTech , #EarlyStageVC , #AIinBiotech Servier Servier Pharmaceuticals Alex Vandier Biotech Investors Database VC Corporate H … ollaborative Drug Discovery - CDD Vault Servier Unveils €200M Strategic Venture Fund to Back Next-Gen Biotech and Therapeutics newnex.io 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Specific Biologics 2,564 followers 5mo Report this post Thanks Nikhil Thatte and Lumira Ventures for the shoutout to Specific Biologics in the #LeadingBeyondTheLab Podcast! We echo that Dualase® genome editors are a game-changing technology - like our first clini … nt. That scale makes the need for diagnostic and data platforms built for broad application clear, reflecting a familiar evolution we saw in genomics as diagnostics moved from single-analyte to multiplex, and ultimately to blood-based approaches as targeted therapies expand.” 🎉 Congratulations to the Precede team as they accelerate access to target and pathway biology aligned with the demands of modern patient care See more below and in Precede’s announcement: https://lnkd.i … to welcome new strategic and institutional partners, including Labcorp Venture Fund, UPMC Enterprises , Mirae Asset Capital Life Science , Mirae Asset Capital , 28 Capital LLC , and Alexandria Venture Investments. We’re also grateful for the commitment and belief of the team at SVB, who support the Precede Bio mission through strategic, non-dilu
Techbio startup Scripta Therapeutics... - Bioscience Today Facebook Log In Bioscience Today's Post Bioscience Today January 29 · Shared with Public Techbio startup Scripta Therapeutics has emerged from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery https://www.biosciencetoday.co.uk/scripta-therapeutics.../ #drugdiscovery #techbio #lifesciences biosciencetoday.co.uk Scripta Therapeutics aims to flip the script on disease-modifying drugs - Bioscience Today Like Comment
Litera Scripta | Bounds Law Library Apply Give myBama 6:32pm 06/27/2026 Expand title bar menu Close title bar menu Search the Law Library's Catalog Submit Information Expand Information menu Close Information menu Hours Location Reference Services Circulation Services Directory Book Study Room Book Equipment Research Expand Research menu Close Research menu Databases Guides Legal Links New Books Special Collections Expand Special Collections menu Close Special Collections menu Manuscript Collections Hugo Black Collection Exhibits Occasional Publications Policies Sample Exams Catalog Litera Scr
--> PRIVACY | Scripta Insights top of page Member Support: (866) 572-7478 CONSULTANTS & PLAN SPONSORS We're the Rx Navigation™ Company Get your members The Right Meds at The Best Price ™, while reducing your pharmacy benefit spend–without changing PBMs. SOLUTIONS Rx Navigator | Fiduciary Protection Program GLP-1 Navigation | Member Incentive Rewards Provider Navigator | Cash Pay Integrations TECHNOLOGY Scripta’s Med Mapper™ AI Software ABOUT Team | Board | P&T Committee CASE STUDIES Realized Savings | Testimonials INSIGHTS Blog | Articles | Resea … se applications or advertising include links to this policy. It does not apply to information collected by: us offline or through any other means, including on any other website operated by Scripta or any third party; any third party, including through any application or content (including advertising) that may link to or be accessible from or on the Website. Note, Scripta is not a medical group. Your Provider is responsible for providing you with a Notice of Pr … Data from children under 18. If you are under 18, your parent or guardian must submit information about you on your behalf. If you are under 18, do not use or provide any information on our Website or on or through any of their features, including your name, address, telephone number, email address, or any screen name or user name you may use. If we learn we have collected or received Personal Data from a child under 18 without verification of parental consent, we will delet … ith your consent. We may also disclose your Personal Data: to enforce or apply our Terms of Use and other agreements, including for billing and collection purposes; and if we believe disclosure is necessary or appropriate to protect the rights, property, or safety of Scripta, our customers, or others. This includes exchanging information with other companies and organizations for the purposes of fraud protection and risk reduction. 5. DISCLOSURE OF YOUR... 6. Choices A … gress tracking, reminders, etc.) and communications. Message and data rates may apply. When you use the Website or our services, or send e-mails, messages, and other communications from your desktop or mobile device to us, you are communicating with us electronically. You consent to receive communications from us electronically. You agree that
Scripta Therapeutics raises $12m in seed funding for Alzheimer disease treatment | Komeil Nasrollahi posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu … recovery startup, secured INR 10 crore ($1.2M) seed investment led by Incubate Fund Asia - Saumaric Dangwal * Allegria Therapeutics , Swiss biotech developing mast cell therapies, raised $5.1M in seed extension funding to advance clinical programs - Maria Van Dongen * Seen Nutrition won $500K at the seventh annual Grow-NY competition, supporting food, beverage, and agriculture expansion in New York - Jennifer Han, PharmD, BCACP * Nationwide Children's Hospital , Columbus, Oh
Scripta Revenue 2025: $9.3M ARR, $27.9M Valuation 00 d : 00 h : 00 m : 00 s AI Growth Summit: 9 Tactics to Add $10m Fast | June 30 121/150 seats taken Save Your Seat Home SaaS Database Add Your Company Podcast Pricing Sections Company Revenue Valuation and Funding Founder and CEO Employees and Team Size FAQ Industries Contacts Competitors SaaS Database / Industries / Other Analytics Software / Scripta Scripta Needham , Massachusetts , United States scriptainsights.com Other Analytics Software Valuation $27.9M 2025 Revenue $9.3M Funding $0 Team 69 Founded 2019 Company Revenue Valuation and Fund
Invest In Scripta Insights Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Scripta Insights Stock Invest in or calculate the value of your shares in Scripta Insights or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Scripta Insights Stock (SCIS) Scripta Insights is a healthcare information technology solution company. Invest Now Sell Shares About Scripta Insights Stock Founded 2010 Headquarters Wellesley, MA, US Indus … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
Scripta Insights Secures Series B Funding, Raises $42M Total, Revolutionizing the Way Americans Shop for Prescription Drugs Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Ga … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Scripta raises $12 million to find disease-modifying drugs - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodi
Flipping the script: Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu 14 Nov 2025 Corporate Flipping the script: Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity $12 million seed funding round led by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advis
Expert Breakdown of Short-Term Forecasting in 5 Minutes | Robert F. Siegmund, PhD MBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … , on the latest episode of Careers in Discovery. Peter talks about how focussed application of AI can meaningfully improve drug discovery, Scripta's unique take on “lab-in-the-loop”, and how we’re using omics to zero in on the drivers of disease—starting with neurodegeneration. You’ll also hear Peter’s personal journey: from an unexpected start, through big pharma and business development, to building a company to “flip the script” on how we find disease-modifying medicines.
Transcription Factors in Alzheimer's Disease Treatment | Scripta Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Rethinking drug discovery through transcription factor biology | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniq … ption factor-driven drug discovery. Scripta Therapeutics was founded in 2025 to apply this approach to neurodegenerative disease, with an initial focus on Alzheimer’s disease. From pharma to platform thinking Founder and CEO Peter Hamley’s interest in transcription factors is rooted in more than two decades of experience across large pharmaceutical organisations and biotech. He began his career at AstraZeneca in the UK before moving to Sanofi, where he led global chemistry gr … 6-05-22T07:38:00 Contributor Dr Helen Bright , By Drug Target Review Whitepaper Application note: Agilent XF real time ATP rate assay 2023-02-13T11:57:11 Sponsored by Agilent Whitepaper Guide: Tips for Single Cell Isolation 2023-03-14T10:07:00 Sponsored by Bio-Techne Whitepaper Consistent, functional lower motor neurons from iPSCs 2024-01-26T13:22:42 Sponsored by bit.bio Load more Topics Technology Resources Diseases Drugs and therapies Research and development Tools and tech
BREAKING NEWS: Oxford-based Scripta Therapeutics has launched with $12M in seed funding to pioneer a platform that targets transcription factors. 🤔 Why it matters: Scripta's biology-up model could… | Joachim Eeckhout | 13 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can up
Scripta Therapeutics raises $12m to flip the script on drug discovery - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Company This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. URL This field is for validation purposes and shou
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Scripta Therapeutics raises $12m to advance neurodegenerative research | News | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and te … ional Strategies 2025-10-08T14:00:00 Sponsored by Eurofins Discovery Whitepaper Application note: Novel screening tools for TMEM175 drug discovery 2023-07-04T09:00:08 Sponsored by SB Drug Discovery Webinar Cancer drug discovery breakthroughs: research that’s changing lives 2025-11-13T14:00:00 Sponsored by Cell Signaling Technology Report Organoids and Organ Chips: Improving Decision-Making in Early Drug Discovery 2026-05-05T13:24:00 Sponsored by HUB Organoids Article Advanced
Scripta Therapeutics News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu Biology decoded, disease undone Modulating transcription factor activity to restore health Drug discovery is coming from the wrong direction: targeting the downstream consequences of disease rather than the underlying biological causes. It’s time to flip the script. By focusing on unde rstanding and manipulating the master controllers of biology, we’re searching for drugs with the pote
Peter Hamley on Careers in Discovery podcast News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu 8 Jan 2026 Insights Peter Hamley on Careers in Discovery podcast Hear from our founder & CEO, Peter Hamley, on the latest episode of Careers in Discovery. Peter talks about how focussed application of AI can meaningfully improve drug discovery, Scripta's unique take on “lab-in-the-loop”, and how we’re using omics to zero in on the drivers of disease—starting with
Scripta Therapeutics | About us News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact News News News Insights Insights Insights Join us Join us Join us Contact Contact Contact Menu Join us We’re an Oxford-based techbio company on a mission to deliver transformative therapeutics through cutting edge technology. Scripta combines a deep understanding of biology with precise knowledge of how to manipulate it. We're building a team of technologists and scientists, working together to push the boundaries of our knowledge of biology and how to alter it. If this sou